Results 121 to 130 of about 24,552 (280)

Gene editing of BTK using CRISPR/Cas9 to study drug resistance in acute myeloid leukaemia

, 2019
Melanie Märken
openalex   +1 more source

Mechanically Robust Biodegradable Stents With Theragenerative Vascular Responses via Combined 3D Printing and Janus Nanoengineering

Advanced Science, Volume 13, Issue 34, 19 June 2026.
This work introduces a theragenerative 3D‐printed biodegradable stent with Janus nanoarchitecture for spatially controlled vascular healing. A luminal tantalum ion–implanted surface accelerates endothelialization and hemocompatibility, while an abluminal sirolimus/poly‐L‐lactic acid–tantalum layer provides sustained drug release and suppresses smooth ...
Jong Hwa Seo, Dong‐Sung Won, Hyun Lee, Seojoon Bang, Hyeong Seok Kang, Ju Yeong Gwon, Chan Ho Moon, Ji Won Kim, Yubeen Park, Minho Kang, Dong Yun Lee, Donghyun Lim, Kisuk Yang, Gi Doo Cha, Soo‐Hong Lee, Tae‐Sik Jang, Seokbeom Kim, Jun‐Kyu Park, Jung‐Hoon Park, Hyun‐Do Jung   +19 more
wiley   +1 more source

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders

Biomolecules
BTK (Bruton’s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL/SLL.
Andrea Duminuco, Paola De Luca, Gaia Stanzione, Laura Anastasia Caruso, Giulio Lavenia, Salvatore Scarso, Bruno Garibaldi, Fanny Erika Palumbo, Calogero Vetro, Giuseppe Alberto Palumbo   +9 more
doaj   +1 more source

Stage‐Dependent Transcriptional Reprogramming of B‐Cell Receptor Signaling and Antigen Presentation During Bovine Leukemia Virus–Driven Lymphomagenesis

Animal Genetics, Volume 57, Issue 3, June 2026.
ABSTRACT Bovine leukemia virus (BLV), an oncogenic deltaretrovirus, establishes lifelong infection in cattle and induces enzootic bovine leukosis in a subset of animals following prolonged latency. Despite extensive evidence of immune dysregulation, stage‐specific transcriptional reprogramming of B cells, the primary viral reservoir remains ...
Mohammad Mehdi Akbarin, Zahra Farjami, Cecilia Rodríguez Murillo, Víctor David González‐Fernández, Gabriel Eduardo Acevedo‐Jiménez, Lucero de María Ávila‐De la Vega, Hugo Ramírez Álvarez   +6 more
wiley   +1 more source

PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) [PDF]

, 2019
Judith Trotman, Stephen Opat, Paula Marlton, David Gottlieb, David Simpson, Gavin Cull, David Ritchie, Emma Verner, Javier Muñoz, Alessandra Tedeschi, Jennifer J. Huang, William Novotny, Medhat Osman, Siminder Atwal, John F. Seymour, Andrew W. Roberts, Constantine S. Tam   +16 more
openalex   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives. [PDF]

Eur J Haematol
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gaidano G, Danesi R.
europepmc   +2 more sources

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1196-1205, June 2026.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

A mohácsi csata egy új képe – az MTA BTK Történettudományi Intézet egy új tanulmánykötete kapcsán

, 2019
Gábor Farkas Farkas
openalex   +2 more sources

Inhibition of bruton’s tyrosine kinase directly alleviates pathogenic CD4+ T cell response via PPAR-γ signaling in autoimmune uveitis

Journal of Neuroinflammation
Background Bruton’s tyrosine kinase (BTK), a key regulator of immune responses, has been extensively studied in B cells and innate immunocytes. Small-molecule BTK inhibitors (BTKi) have shown remarkable efficacy in multiple preclinical and clinical ...
Zhiqiang Xiao, Zhuang Li, Wenjie Zhu, Guanyu Chen, Xiaoshuang Luo, Zhiqing Mai, Minzhen Wang, Haixiang Huang, Zuoyi Li, Yuxun Shi, Yanyan Xie, Hao Wu, Xiaoqing Chen, Dan Liang   +13 more
doaj   +1 more source

BTK Inhibitors Differentially Induce Apoptosis but Similarly Suppress Chemotaxis and Lipid Accumulation in Mantle Cell Lymphoma [PDF]

, 2020
Zhuojun Liu, Jia Liu, Tainming Zhang, Lin Li, Shuo Zhang, Hao Jia, Yuanshi Xia, Mingxia Shi, Jing Zhang, Shuhua Yue, Xiaofang Chen, Jian Yu   +11 more
openalex   +1 more source